Evidence map›Paper›PMID 42725674›Full record

ArticlemAbs2026

HDX-MS-Guided computational modeling for rapid and accurate antibody-antigen interface mapping.

Will McMahon, Hanzhi Zhang, Xiuling Li, Vaheh Oganesyan, Sterling Payne, Nurjahan Mehzabeen, Nydia van Dyk, Wenhai Liu, Wesley Howard, Pengyi Zhao and 5 more

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Will McMahonAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
Hanzhi ZhangBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Xiuling LiBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Vaheh OganesyanBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Sterling PayneBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Nurjahan MehzabeenBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Nydia van DykBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Wenhai LiuBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Wesley HowardAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
Pengyi ZhaoAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
Yeying ZhangAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
Mulin FangAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
Xiaoyu ChenAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
Yariv MazorBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Yu ShiAnalytical Sciences, Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0001-6191-4787

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate mapping of paratopes and epitopes at antibody-antigen (Ab-Ag) interfaces is essential for the rational design of therapeutic antibodies in early drug development. Traditional methods for determining high-resolution Ab-Ag complex structures, such as X-ray crystallography and cryo-electron microscopy, are labor-intensive and require substantial time and resources. Although recent computational approaches have increased throughput, prediction accuracy and reliability remain limited, particularly without experimental structural constraints. Here, we present a hydrogen-deuterium exchange mass spectrometry (HDX-MS)-guided structural modeling workflow for efficient and accurate epitope and paratope mapping across three prospective case studies in therapeutic protein discovery and engineering. Across these systems, peptide-level HDX-MS data were sufficient to guide docking and structural modeling, whereas targeted electron transfer dissociation (ETD) HDX-MS was applied in one system as a higher-resolution, orthogonal approach to further localize critical binding residues. The workflow was applied to diverse Ab-Ag architectures spanning Fab and VHH binders and homodimeric and heterodimeric antigen ectodomains, and HDX-MS data were integrated with HADDOCK, AlphaFold2, and Protenix to generate Ab-Ag complex models. Comparison with subsequently obtained in-house X-ray crystal structures, used here as orthogonal high-resolution reference structures, showed strong agreement in overall binding orientation and interface placement. These results demonstrate the robustness and practical utility of this integrative approach for structure-informed antibody engineering in therapeutic protein discovery.

Indexed as

Antigen-Antibody ComplexEpitope MappingEpitopesHydrogen Deuterium Exchange-Mass SpectrometryCrystallography, X-RayHumansImmunoglobulin Fab FragmentsModels, MolecularAntigen-Antibody ComplexEpitopesImmunoglobulin Fab FragmentsAntibody-antigen interface mappingcomputational modelingHDX-MS

Identifiers

PMID42725674
PMCPMC13577250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.